Nasal polyps are benign growths that develop in the paranasal sinuses and the nasal lining. In general, it has a teardrop form and is golden brown or pink in hue. The size of the polyps might vary, and they can grow in clusters or on their own. These can lead to serious infections and breathing problems, as well as sleep apnea in some circumstances. Nasal polyps can be caused by asthma, allergy diseases, sinus infections, cystic fibrosis, and other conditions. There are no specific symptoms that develop, however a nasal lining inflammation can ensue.
Market Drivers for Nasal Polyps Treatment Around the World
The global Nasal Polyps Treatment Market is predicted to increase due to key companies' ongoing focus on finding unique ways for treating nasal polyps. For example, in April 2018, Intersect ENT Inc. released SINUVA, a product. It's a sinus implant that's used to treat polyps in the nose. It is a novel therapeutic option for people who have had previous sinus surgery. 1.35 mg mometasone furoate is given directly to the polyps in this implant. It is implanted for a specific time period (90 days).
Regional Analysis of the Global Nasal Polyps Treatment Market
The worldwide nasal polyps treatment market is likely to be dominated by North America. Nasal polyps treatment market growth in North America is predicted to be aided by factors such as a higher prevalence of asthma. Asthma triggers nasal polyps, while nasal polyps can also cause asthma. According to research published by the American Academy of Allergy, Asthma & Immunology in 2017, around 28 percent to 40 percent of people with nasal polyps had asthma.
Key Players in the Nasal Polyps Treatment Market
Regional Analysis of the Global Nasal Polyps Treatment Market
The worldwide nasal polyps treatment market is likely to be dominated by North America. Nasal polyps treatment market growth in North America is predicted to be aided by factors such as a higher prevalence of asthma. Asthma triggers nasal polyps, while nasal polyps can also cause asthma. According to research published by the American Academy of Allergy, Asthma & Immunology in 2017, around 28 percent to 40 percent of people with nasal polyps had asthma.
Key Players in the Nasal Polyps Treatment Market
Intersect ENT Inc., GlaxoSmithKline Plc, Merck Sharp and Dohme Corp, Teva Branded Pharmaceutical Products R and D Inc., Norton Waterford Ltd, Sanofi, Regeneron Pharmaceuticals Inc., Fougera Pharmaceuticals Inc., Glenmark, and Taro Pharmaceuticals Industries Ltd. are some of the major players in the global nasal polyps treatment market.
0 Comments